Core Viewpoint - Furuya Medical Technology (01696) has launched the PixelPeel safe laser skin rejuvenation treatment to meet the growing demand for safe, effective, and short-recovery skin renewal procedures [1] Group 1: Product Launch - The PixelPeel treatment has been introduced in North America and is planned for gradual global rollout [1] - PixelPeel utilizes clinically recognized gold standard laser energy combined with pixel-level precision and Alma's proprietary MotionSync technology to ensure a safe, uniform, and controllable treatment process [1] Group 2: Target Audience and Benefits - The treatment is suitable for both first-time users and individuals seeking long-term skin maintenance [1] - PixelPeel offers effective clinical results with a short recovery period and is applicable to various skin types [1] Group 3: Market Impact - The company believes that PixelPeel will provide advanced treatment options that meet current market demands, offering a more convenient and efficient skin care experience [1] - The comprehensive application of PixelPeel in Alma Pixel and Alma Hybrid devices aims to expand market coverage and enhance the purchase and usage rates of these devices [1]

Core Viewpoint - The company has launched the PixelPeel™ safe laser skin rejuvenation treatment to meet the growing demand for safe, effective, and short-recovery skin renewal procedures, initially debuting in North America with plans for global expansion [1] Group 1: Product Details - PixelPeel™ utilizes clinically recognized gold standard laser energy combined with pixel-level precision and Alma's proprietary MotionSync™ technology to ensure a safe, uniform, and controllable treatment process [1] - The treatment effectively improves skin texture, tone, and brightness, making it suitable for both first-time users and those seeking long-term skin maintenance [1] - The solution offers high clinical efficacy with a short recovery period and is applicable to various skin types [1] Group 2: Market Impact - The company believes that PixelPeel™ will provide advanced treatment options that align with current market demands, offering a more convenient and efficient skin care experience for medical institutions and consumers [1] - The comprehensive application of PixelPeel™ in Alma Pixel™ and Alma Hybrid devices aims to expand the market coverage of existing equipment systems, thereby increasing procurement and usage rates [1]

Core Viewpoint - The company has launched the PixelPeel™ safe laser skin rejuvenation treatment to meet the growing demand for safe, effective, and short recovery skin renewal procedures, initially introduced in North America with plans for global expansion [1] Group 1: Product Details - PixelPeel™ utilizes clinically recognized gold standard laser energy combined with pixel-level precision and Alma's proprietary MotionSync™ technology to ensure a safe, uniform, and controllable treatment process [1] - The treatment effectively improves skin texture, tone, and brightness, making it suitable for both first-time users and those seeking long-term skin maintenance [1] - The solution offers high clinical efficacy with a short recovery period and is applicable to various skin types [1] Group 2: Market Impact - The company believes that PixelPeel™ will provide advanced treatment options that align with current market demands, offering a more convenient and efficient skin care experience for medical institutions and consumers [1] - The comprehensive application of PixelPeel™ in Alma Pixel™ and Alma Hybrid devices aims to create a new treatment solution, further expanding the market coverage of existing device systems and enhancing their purchase and usage rates [1]

Financial Data and Key Metrics Changes - The company reported revenue of $165.5 million for H1 2025, a decrease of approximately 1.9% compared to the previous year, primarily due to challenging market conditions such as high interest rates and weakened consumer spending in North America [8][14][18] - Gross profit margin was 60%, down 2.4 percentage points year over year, attributed to a shift in product mix towards higher-cost professional products and lower revenue contribution from North America [15][16] - Adjusted net profit was $12 million, reflecting a decline of 28.1% year over year [16] Business Line Data and Key Metrics Changes - Medical aesthetics products remained the largest revenue contributor, generating $137.7 million, or 83.2% of total revenue [16] - The injectables segment saw significant growth, increasing by 280.1% to $14.4 million, representing 8.7% of total revenue, up from 2.7% [16] Market Data and Key Metrics Changes - International sales channels grew by 7.1% year over year, with the Asia Pacific region achieving double-digit growth of 17.6%, driven by strong performance in Thailand and Korea [10][14] - The company’s direct operations worldwide provided robust market access and execution capabilities, allowing it to offset regional challenges [10] Company Strategy and Development Direction - The company is transitioning to a holistic ecosystem partner in medical aesthetics, integrating energy-based devices, injectables, and personalized skincare [4][5] - Future focus includes strengthening corporate leadership in Asia Pacific and North America, with anticipated launches of new products like Dexify in China [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in regaining momentum in regions affected by geopolitical tensions and anticipated stronger performance in H2 2025 due to increased consumer confidence and demand for recent launches [11][12] - The company plans to continue expanding its unique wellness ecosystem and deepen relationships with clinics and end consumers [12] Other Important Information - The successful North American launch of Universe Skin by Alma, an AI-assisted skincare system, is a key milestone for the company [5] - The company is preparing for the launch of Dexify, the world's first peptide-powered botulinum toxin in Mainland China, and expanding its injectable portfolio in various regions [12][15] Q&A Session Summary Question: What is the main reason for the good performance in the APAC area? - Growth in Thailand was driven by the introduction of Profilo, while Korea benefited from existing direct operations and the concept of lifting using titanium [20][22] Question: What is the proportion of direct sales in the first half of the year? - Approximately 85% of the business was from direct operations, slightly down due to a shift towards distributor fulfillment in North America [24][25] Question: What are the main reasons for the decrease in North America performance? - High interest rates and consumer spending concerns led to delays in deal closures and order processing [29][32] Question: What is the current progress of the launch of Dexify in China? - The company is advancing phase three clinical trials for Dexify and expects to launch in H2 2025, aiming for significant sales growth in the following years [55][56] Question: What are the differences among the injectable products? - The company offers a range of injectables including neotoxins, volumetric fillers, and biostimulators, each serving different clinical needs [60][62] Question: What is the guidance on revenue and net profit for 2025? - The company expects growth in both revenue and net profit in the second half of 2025, driven by new product launches and a backlog of orders [70][72]